A radiation-controlled molecular switch for use in gene therapy of cancer

Gene Therapy

Volumn 7, Issue 13, 2000, Pages 1121-1125

  Scott, S D ^a,d   Marples, B ^a,d   Hendry, J H ^a   Lashford, L S ^a   Embleton, M J ^b   Hunter, R D ^c   Howell, A ^b   Margison, G P ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Department of Medical Oncology ^*  (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

CRE recombinase; Ganciclovir; HSVtk; Molecular switch; Radiation responsive elements; Radiotherapy

Indexed keywords

ARTICLE; BACTERIOPHAGE P1; CANCER THERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOMEGALOVIRUS; EXPRESSION VECTOR; GENE CONTROL; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC RECOMBINATION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROMOTER REGION; RADIATION DOSE; RADIATION RESPONSE;

EID: 0033925131     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301223     Document Type: Article

References (39)

1. Weichselbaum RR, Hallahan DE, Fuks Z, Kufe DW. Radiation induction of immediate early genes: effectors of the radiation stress response. Int J Radiat Oncol Biol Phys 1994; 30: 229-234.
2. Weichselbaum RR et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 1994; 54: 4266-4269.
3. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy to cancer: a review. Oncol Res 1997; 9: 313-325.
4. Weichselbaum RR, Kufe D. Gene therapy of cancer. Lancet 1997; 349: SII10-SII12.
5. Hallahan DE, Weichselbaum R. Role of gene therapy in radiation oncology. Cancer Treat Res 1998; 93: 153-167.
6. Hallahan DE et al. Spatial and temporal control of gene therapy using ionizing radiation. Nature Med 1995; 1: 786-791.
7. Jahroudi N, Ardekani AM, Greenberger JS. Ionizing irradiation increases transcription of the von Willebrand factor gene in endothelial cells. Blood 1996; 88: 3801-3814.
8. Joki T, Nakamura M, Ohno T. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum Gene Ther 1995; 6: 1507-1513.
9. Takahashi T, Namiki Y, Ohno T. Induction of the suicide HSV TK gene by activation of the Egr 1 promoter with radioisotopes. Hum Gene Ther 1997; 8: 827-833.
10. Datta R et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA 1992; 89: 10149-10153.
11. 6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA 1993; 90: 2419-2422.
12. Marples B et al. Development of synthetic promoters for radiation-mediated gene therapy. Gene Therapy 2000; 7: 511-517.
13. Sternberg N, Hamilton D, Hoess R. Bacteriophage P1 site-specific recombination. II. Recombination between loxP and the bacterial chromosome. J Mol Biol 1981; 150: 487-507.
14. Sauer B, Henderson N. Cre-stimulated recombination at loxP-containing DNA sequences placed into the mammalian genome. Nucleic Acids Res 1989; 17: 147-161.
15. Kilby NJ, Snaith MR, Murray JA. Site-specific recombinases: tools for genome engineering. Trends Genet 1993; 9: 413-421.
16. Anton M, Graham FL. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J Virol 1995; 69: 4600-4606.
17. Guo Z et al. Efficient and sustained transgene expression in mature rat oligodendrocytes in primary culture. J Neurosci Res 1996; 43: 32-41.
18. Bartlett RJ et al. Long-term expression of a fluorescent reporter gene via direct injection of plasmid vector into mouse skeletal muscle: comparison of human creatine kinase and CMV promoter expression levels in vivo. Cell Transplant 1996; 5: 411-419.
19. Ropp JD et al. Aequorea green fluorescent protein analysis by flow cytometry. Cytometry 1995; 21: 309-317.
20. Lybarger L, Dempsey D, Franek KJ, Chervenak R. Rapid generation and flow cytometric analysis of stable GFP-expressing cells. Cytometry 1996; 25: 211-220.
21. Wagner MJ, Sharp JA, Summers WC. Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1. Proc Natl Acad Sci USA 1981; 78: 1441-1445.
22. Kim JH, Kim SH, Brown SL, Freytag SO. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res 1994; 54: 6053-6056.
23. Manome Y et al. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther 1998; 9: 1409-1417.
24. Elshami AA et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85-92.
25. Denning C, Pitts JD. Bystander effects of different enzyme-pro-drug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 1997; 8: 1825-1835.
26. Duflot-Dancer A et al. Long-term connexin-mediated bystander effect in highly tumorigenic human cells in vivo in herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Therapy 1998; 5: 1372-1378.
27. Kianmanesh AR et al. 'Distant' bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther 1997; 8: 1807-1814.
28. Misawa T et al. Development of systemic immunologic responses against hepatic metastases during gene therapy for peritoneal carcinomatosis with retroviral HS-tk and ganciclovir. J Gastrointest Surg 1997; 1: 527-533.
29. Wilson KM et al. HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect. Arch Otolaryngol Head Neck Surg 1996; 122: 746-749.
30. Elliott G, O'Hare P. Intercellular trafficking of VP22-GFP fusion proteins. Gene Therapy 1999; 6: 149-151.
31. Kanegai Y et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res 1995; 23: 3816-3821.
32. Sakai K, Mitani K, Miyazaki J. Efficient regulation of gene expression by adenovirus vector-mediated delivery of the CRE recombinase. Biochem Biophys Res Comm 1995; 217: 393-401.
33. Lasko M et al. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci USA 1992; 98: 6232-6236.
34. Sato Y et al. Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. Biochem Biophys Res Comm 1998; 244: 455-462.
35. Anderson WR. Human gene therapy. Nature 1998; 392: 25-30.
36. Mullen CA, Petropoulos D, Lowe RM. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res 1996; 56: 1361-1366.
37. Hart IR. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol 1996; 23: 154-158.
38. Prince HM. Gene transfer: a review of methods and applications. Pathology 1998; 30: 335-347.
39. http://www.nih.gov/news/panelrep.html